676496
VEGF Inhibitor, CBO-P11
The VEGF Inhibitor, CBO-P11 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
VEGF Inhibitor, CBO-P11, Cyclo-VEGI, cyclic( D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI, Cyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
Empirical Formula (Hill Notation):
C90H140N28O22S
Molecular Weight:
1998.31
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥97% (HPLC)
form
lyophilized solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
color
white
solubility
DMSO: 5 mg/mL
water: soluble
shipped in
wet ice
storage temp.
−20°C
General description
A macrocyclic 17-amino acid peptide derived from residues 79 - 93 of vascular endothelial growth factor that mediate its binding to VEGFR-2. It blocks the binding of VEGF165 to its receptors (IC50 = 700 nM for VEGFR1, 1.3 µM for VEGFR2) and exhibits anti-angiogenic activity as well as other VEGFR-mediated cellular functions, such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Its anti-angiogenic activity has been successfully demonstrated in vivo using chick embryos and nude mice tumor models of human intracranial and syngeneic glioma.
A macrocyclic, 17-amino acid peptide derived from residues 79-93 of vascular endothelial growth factor (VEGF) that mediates the binding of VEGF to its receptor, VEGFR-2. Blocks the binding of VEGF165 to its receptors (IC50 = 70 nM for VEGFR-1, 1.3 µM for VEGFR-2) and exhibits anti-angiogenic properties. Also reported to block other VEGF-mediated cellular functions such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Also reported to exhibit anti-angiogenic properties in vivo using chick embryo and nude mouse tumor models of human intracranial and syngeneic glioma.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Blocks the binding of VEGF165 to its receptors
Blocks the binding of VEGF165 to its receptors
Product does not compete with ATP.
Reversible: no
Target IC50: 700 nM for VEGFR1, 1.3 µM for VEGFR2
Packaging
Packaged under inert gas
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Sequence
cyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)
Physical form
Supplied as a trifluoroacetate salt.
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Zilberberg, L., et al. 2003. J. Biol. Chem.278, 35564.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service